Alpha Compute Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Brittany Kaiser

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

Seeking Alpha • Aug 29

Portage Biotech GAAP EPS of -$0.13

Portage Biotech press release (NASDAQ:PRTG): Q1 GAAP EPS of -$0.13. As of June 30, 2022, the Company had cash and cash equivalents of approximately $21.2 million.

Seeking Alpha • Jul 20

Portage Biotech rises after getting full ownership of its anti-cancer agonist platform

Portage Biotech (NASDAQ:PRTG) stock has added 16.8% to $10.95 in Wednesday morning trading, after the company said it had acquired the remaining ownership interest in its invariant natural killer T cell (iNKT cell) agonist platform. iNKT cells play an important role in anti-tumor immune responses. PRTG's synthetic iNKT agonists activate and expand important immune system components and immune attacks against cancer. With the acquisition of the about 22% remaining ownership interest, PRTG now fully owns the worldwide rights to its iNKT agonists, including lead programs PORT-2 and PORT-3. The acquisition was done through PRTG's unit iOx Therapeutics from the founding equity holders in exchange for 1.07M shares of Portage (PRTG). Additionally, a payment of $25M in PRTG shares or cash would be triggered upon the achievement of a certain clinical milestone in the PORT-2 or PORT-3 programs.

Seeking Alpha • Jul 06

Portage Biotech acquires Tarus Therapeutics, a developer of adenosine receptor antagonists

Portage Biotech (NASDAQ:PRTG) on Wednesday said it would acquire privately-held Tarus Therapeutics in exchange for about 2.4M PRTG shares and the assumption of $3M in liabilities. The acquisition of Tarus allows PRTG to acquire two clinical-stage adenosine compounds and two preclinical assets for a ~$21M upfront consideration. The deal also calls for additional payments of up to $32M in PRTG shares or cash upon achievement of certain milestones. As per the deal, Robert Glassman, a former independent director of Tarus, will join PRTG's board. PRTG also said it had entered into a committed share purchase agreement for up to $30M with Chicago-based institutional investor Lincoln Park Capital Fund LLC, the proceeds of which will potentially extend PRTG's cash runway into 2024. PRTG stock earlier closed +2.5% at $7.72.

CEO

Brittany Kaiser (37 yo)

less than a year

Tenure

Ms. Brittany Kaiser has been a Member of the Advisory Board of Hamak Strategy Limited (formerly known as Hamak Gold Limited) since September 11, 2025. She serves as CEO & Director at Alpha Compute Corp (fo...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Robert Kramer	Chief Scientific Officer	7.4yrs	US$119.25k	0.021% $ 1.4k
Fiorenzo Villani	Executive Chairman & Chief Investment Officer	less than a year	geen gegevens	geen gegevens
Brittany Kaiser	CEO & Director	less than a year	geen gegevens	geen gegevens
Wesley Levitt	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Logan Golema	Chief Technology Officer	less than a year	geen gegevens	geen gegevens
William De'Ath	Chief Partnership Officer	less than a year	geen gegevens	geen gegevens
Adam Melero	Controller	1.8yrs	geen gegevens	geen gegevens
Peter Molloy	Chief Executive Officer of Cyncado Therapeutics Inc.	1.4yrs	geen gegevens	geen gegevens

0.8yrs

Gemiddelde duur

46.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ALP wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Fiorenzo Villani	Executive Chairman & Chief Investment Officer	less than a year	geen gegevens	geen gegevens
Brittany Kaiser	CEO & Director	less than a year	geen gegevens	geen gegevens
Jean-Christophe Renondin	Director	2.2yrs	US$126.99k	0% $ 0
Gregory Bailey	Independent Lead Director	13yrs	US$30.00k	2.13% $ 133.9k
James Mellon	Independent Director	4.3yrs	US$30.00k	1.15% $ 72.5k
F. Siciliano	Director	less than a year	geen gegevens	geen gegevens
Tom Richer	Member of Advisory Board	less than a year	geen gegevens	geen gegevens

0.8yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ALP wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw bestuur.

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/06/10 18:38
Aandelenkoers aan het einde van de dag	2026/06/10 00:00
Inkomsten	2025/09/30
Jaarlijkse inkomsten	2025/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Alpha Compute Corp wordt gevolgd door 4 analisten. 1 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Justin Walsh	B. Riley Securities, Inc.
Li Wang Watsek	Cantor Fitzgerald & Co.
Kevin Dede	H.C. Wainwright & Co.

Alpha Compute Beheer

Beheer criteriumcontroles 0/4

Belangrijke informatie

Recente managementupdates

Alpha Compute Corp. Appoints Tom Richer to Advisory Board

Less than half of directors are independent

AlphaTON Capital Corp. Announces Board Changes, Effective February 6, 2026

AlphaTON Capital Corp. Announces the Appointment of Logan Ryan Golema as Chief Technology Officer

AlphaTON Capital Corp. Appoints William De’Ath as Chief Partnership Officer

AlphaTON Capital Corp. Appoints Wes Levitt as Chief Financial Officer, October 24, 2025

Recent updates

New major risk - Share price stability

Alpha Compute Confirms That Its First Large-Scale GPU Cluster Is Now in Final Testing and Is Targeted to Hand over to AI Compute Customers on May 8, 2026

Alpha Compute Corp. Appoints Tom Richer to Advisory Board

AlphaTON Capital Corp. announced that it expects to receive $43 million in funding from Vertical Data Inc.

AlphaTON Capital Corp. has filed a Follow-on Equity Offering in the amount of $400 million.

Less than half of directors are independent

AlphaTON Capital Corp. Announces Board Changes, Effective February 6, 2026

AlphaTON Capital Corp. Launches Claude Connector Powered by TON & Telegram

AlphaTON Capital Corp. has completed a Follow-on Equity Offering in the amount of $14.999023 million.

AlphaTON Capital Corp. has filed a Follow-on Equity Offering in the amount of $14.999023 million.

New major risk - Market cap size

AlphaTON Capital Corp. Announces the Appointment of Logan Ryan Golema as Chief Technology Officer

Cyncado Therapeutics and Tarus Therapeutics, Llc Announces A Non-Binding Letter of Intent (Loi)

AlphaTON Capital Corp. Appoints William De’Ath as Chief Partnership Officer

Tarus Therapeutics, LLC Announces A Poster Presentation At the Society for Immunotherapy of Cancer Annual Meeting

AlphaTON Capital Corp and Tarus Therapeutics, LLC Announces Preclinical Mesothelioma Data Show Direct A2b Tumor Activity

AlphaTON Capital Corp. Appoints Wes Levitt as Chief Financial Officer, October 24, 2025

AlphaTON Capital Corp and Cyncado Therapeutics Announce First Evidence That Selective A2b Receptor Inhibition Lowers Pd-L1 Tumor Expression and Directly Suppresses Mesothelioma Tumor Growth

Alphaton Capital Corp. Launches Ai Vertical with Morpheusai to Accelerate Agentic Ai Development on Ton and Telegram

New major risk - Share price stability

AlphaTON Capital Corp. (NasdaqCM:ATON) entered into a non-binding letter of intent to acquire 51% stake in Gamee Limited from Animoca Brands Limited.

AlphaTON Capital Corp. announced that it has received $36.2136 million in funding

Less than half of directors are independent

Portage Biotech Inc. has filed a Follow-on Equity Offering in the amount of $2.84145 million.

New major risk - Negative shareholders equity

Portage Biotech Inc. has filed a Follow-on Equity Offering in the amount of $3.37725 million.

New major risk - Market cap size

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of Port-7

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial

New major risk - Shareholder dilution

Portage Biotech Receives Extension of Time to Attain Compliance with Stock Exchange Continued Listing Requirements

Portage Biotech Inc. Appoints Peter Molloy as CEO of Subsidiary, Cyncado Therapeutics, Inc

New major risk - Revenue and earnings growth

Less than half of directors are independent

Portage Biotech Inc. Appoints Alexander Pickett as Chief Executive Officer, Effective December 15, 2024

Portage Biotech Inc. Appoints Alexander Pickett to Board of Directors, Effective December 15, 2024

Price target decreased by 22% to US$140

Portage Biotech Inc. Announces Chief Financial Officer Changes

Portage Biotech Inc. announced delayed 20-F filing

Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives

New major risk - Financial position

New major risk - Market cap size

Portage Biotech Inc. Presents Updates on its iNKT and Adenosine Programs at the Society for Immunotherapy of Cancer's 38th Annual Meeting

New major risk - Revenue and earnings growth

New major risk - Share price stability

Price target decreased by 16% to US$16.00

Portage Biotech Inc. Announces First Patient Dosed in Phase 1A Trial of Portage-6 in Select Solid Tumors

Portage Biotech Reports Updated Interim Data for Lead Inkt Engager, Port-2, in A Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer At the 2023 American Society for Clinical Oncology (Asco) Annual Meeting

Portage Biotech Inc. Presents Updated Data on the Phase 1/2 Trial Evaluating Port-2 At the Society for Immunotherapy of Cancer’S (Sitc) 37Th Annual Meeting

Portage Biotech Inc., Annual General Meeting, Nov 10, 2022

Portage Biotech Inc. Provides Research and Development Update

Portage Biotech GAAP EPS of -$0.13

Portage Biotech Inc. Announces Leadership Updates

Portage Biotech rises after getting full ownership of its anti-cancer agonist platform

Portage Biotech Inc. (NasdaqCM:PRTG) signed an agreement to acquire Tarus Therapeutics, Inc. for $53.3 million.

Robert Glassman to Join Portage Biotech Inc. Board of Directors

Portage Biotech acquires Tarus Therapeutics, a developer of adenosine receptor antagonists

Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

Portage Biotech Inc. Provides an Update on Its Clinical Development Programs and Announces Its Development Goals for the Remainder of 2022

Portage Biotech Announces Executive Changes

Portage Biotech Inc. Highlights First Patient Dosed in Imp-Mel Study of Port-2 for the Treatment of Melanoma and Non-Small Cell Lung Cancer (Nsclc)

Portage Biotech Inc. has completed a Follow-on Equity Offering in the amount of $23 million.

Portage Biotech Inc. Highlights Safety and Survival Data from Intensity Therapeutics' It-01 Study of Int230-6 (Port-1) At Asco 2021 Annual Meeting

Juvenescence Ltd. acquired Portage pharmaceuticals Ltd from Portage Biotech Inc. (NasdaqCM:PRTG).

Portage Biotech's Common Shares Deleted from Other OTC

Portage Biotech Inc. announced that it has received $6.98145 million in funding

Portage Biotech Inc. announced that it has received $6.7886 million in funding

CEO

Leiderschapsteam